Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Schreuer · SciRah

Researcher profile · Semantic Scholar

M. Schreuer

Share profile

M. Schreuer — researcher profile on SciRah

h-index: 11
Works: 26
Citations: 826

Most-cited papers

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
J. D. de Filette, Y. Jansen, M. Schreuer, H. Everaert +3 more
2016Journal of Clinical Endocrinology and Metabolism214 citations Open access
Semantic Scholar
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.
M. Schreuer, Y. Jansen, S. Planken, I. Chevolet +3 more
2017The Lancet Oncology173 citations
Semantic Scholar
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
M. Schreuer, G. Meersseman, Sari Van Den Herrewegen, Y. Jansen +8 more
2016Journal of Translational Medicine137 citations Open access
Semantic Scholar
Peritumoral indoleamine 2,3‐dioxygenase expression in melanoma: an early marker of resistance to immune control?
I. Chevolet, R. Speeckaert, M. Haspeslagh, B. Neyns +5 more
2014British Journal of Dermatology63 citations
Semantic Scholar
Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma
I. Chevolet, R. Speeckaert, M. Schreuer, B. Neyns +5 more
2015Journal of Translational Medicine61 citations Open access
Semantic Scholar
Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
Y. Jansen, P. Janssens, A. Hoorens, M. Schreuer +3 more
2015Melanoma research42 citations
Semantic Scholar
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
T. Seremet, A. Koch, Y. Jansen, M. Schreuer +11 more
2016Journal of Translational Medicine35 citations Open access
Semantic Scholar
Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy
T. Seremet, S. Planken, M. Schreuer, Y. Jansen +6 more
2018Melanoma research21 citations
Semantic Scholar
Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma
M. Schreuer, G. Meersseman, Sari van Den Herrewegen, Y. Jansen +6 more
2016Melanoma research19 citations
Semantic Scholar
Systemic immune changes associated with adjuvant interferon-&agr;2b-therapy in stage III melanoma patients: failure at the effector phase?
I. Chevolet, M. Schreuer, R. Speeckaert, B. Neyns +7 more
2015Melanoma research14 citations
Semantic Scholar
Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
T. Seremet, D. Liénard, M. Suppa, A. Trepant +7 more
2015Melanoma research12 citations
Semantic Scholar
Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure
M. Schreuer, I. Chevolet, Y. Jansen, T. Seremet +4 more
2015Melanoma research11 citations
Semantic Scholar
Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO)
Y. Jansen, E. Rozeman, L. Højberg, M. H. Geukes Foppen +9 more
20165 citations Open access
Semantic Scholar
Single-center "real life experience" with pembrolizumab (PEMBRO) in pretreated advanced melanoma patients.
Y. Jansen, M. Schreuer, B. Neyns
20164 citations
Semantic Scholar
Quantitative assessment of BRAF V600 mutant cell-free tumor DNA from plasma as a diagnostic and therapeutic biomarker in pts with BRAF V600 mutant melanoma
M. Schreuer, G. Meersseman, Y. Jansen, T. Seremet +5 more
20154 citations
Semantic Scholar
3328 A randomized controlled phase II clinical trial on autologous monocyte-derived mRNA electroporated dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases
Y. Jansen, J. Corthals, S. Wilgenhof, M. Schreuer +3 more
20153 citations
Semantic Scholar
Effect of 5‐Bromodeoxyuridine on Differentiation
M. Schreuer, G. Czihak
19783 citations
Semantic Scholar
Effect of 5-bromodeoxyuridine on differentiation. I. Probability distribution of BUdR-containing DNA-strands in subsequent divisions.
M. Schreuer, G. Czihak
1978Differentiation; research in biological diversity2 citations
Semantic Scholar
The ION-Ghent guidelines for the management of immune related adverse events (irAE's)
V. Kruse, M. Schreuer, K. Vermaelen, P. Ost +3 more
20171 citations
Semantic Scholar
Abstract B003: A randomized controlled phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases
B. Neyns, Y. Jansen, J. Corthals, S. Wilgenhof +3 more
20161 citations
Semantic Scholar
COMBI-rechallenge: a phase II clinical trial on dabrafenib plus trametinib in BRAFV600-mutant melanoma patients who previously experienced progression on BRAF(+MEK)-inhibition
M. Schreuer, V. Kruse, Y. Jansen, B. Neyns
20161 citations Open access
Semantic Scholar
Identification of a predictive signature based on immunohistochemical (IHC), RNA-seq and epigenetic profiling of melanoma metastases for response to ipilimumab-based immunotherapy
T. Seremet, A. Koch, S. Wilgenhof, M. Schreuer +9 more
20151 citations
Semantic Scholar
Severe treatment-induced inflammatory polyarthritis in advanced melanoma patients: 2 case reports
J. Lauwyck, M. Schreuer, Laurent Méric de Bellefon, J. Van Erps +2 more
2022Melanoma research0 citations
Semantic Scholar
Correlation between baseline characteristics and clinical outcome of patients with pretreated advanced melanoma who received pembrolizumab (PEMBRO) in an expanded access program (EAP).
E. Rozeman, Y. Jansen, M. G. Foppen, M. Schreuer +5 more
20160 citations
Semantic Scholar
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
T. Seremet, A. Koch, Y. Jansen, M. Schreuer +11 more
2016Journal of Translational Medicine0 citations Open access
Semantic Scholar
Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma
I. Chevolet, R. Speeckaert, M. Schreuer, B. Neyns +5 more
2015Journal of Translational Medicine0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Neyns×21
Invite
B. Neyns — researcher profile on SciRah
Y. Jansen×18
Invite
Y. Jansen — researcher profile on SciRah
T. Seremet×11
Invite
T. Seremet — researcher profile on SciRah
S. Wilgenhof×11
Invite
S. Wilgenhof — researcher profile on SciRah

×9

Invite

I. Chevolet — researcher profile on SciRah

V. del Marmol×6

Invite

V. del Marmol — researcher profile on SciRah

Invite

D. Liénard — researcher profile on SciRah

Invite

V. Kruse — researcher profile on SciRah

Invite

L. Brochez — researcher profile on SciRah

K. Thielemans×5

Invite

K. Thielemans — researcher profile on SciRah

R. Speeckaert×4

Invite

R. Speeckaert — researcher profile on SciRah

Invite

M. Van Gele — researcher profile on SciRah